Clinuvel Pharmaceuticals Limited (CLVLF) Fair Value & Analysis
Healthcare · US · Market cap $320M
Clinuvel Pharmaceuticals Limited
CLVLF · US
Fair value as of: Jul 15, 2026
From 24 valuation models · updated 8 days ago
Price vs Fair Value (12 months)
12‑month range $6.10 – $11.45 · fair‑value band $11.84 – $19.73 · the $6.10 price screens below the $15.78 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Clinuvel Pharmaceuticals Limited (CLVLF) currently trades at $6.10, while our model-based Fair Value estimate is $15.78, implying the stock looks roughly 158.7% undervalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Clinuvel Pharmaceuticals Limited generated revenue of $96.3M at a net margin of 33.8%. Revenue grew 3.6% year over year. It earns a return on equity of 14.0%. The balance sheet holds a net cash position of $224M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $11.84 (bear case) to $19.73 (bull case); at $6.10, the current price sits below that range. The share trades about 29% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at 159%, CLVLF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Clinuvel Pharmaceuticals Limited reported revenue of $95.0M in FY2025 versus $48.3M in FY2021, a compound +18.4%/yr. Reported net income was $36.2M in FY2025, compounding +10.0%/yr from FY2021.
Is CLVLF fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 183,600 KRW | 76,325 KRW | -58% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,656 | kr 524.15 | -68% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Clinuvel Pharmaceuticals Limited (CLVLF) undervalued?
What is the fair value of CLVLF?
What is the quality score of CLVLF?
What is the revenue of Clinuvel Pharmaceuticals Limited (CLVLF)?
What is the net profit margin of CLVLF?
Does Clinuvel Pharmaceuticals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Clinuvel Pharmaceuticals Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.